[
    [
        {
            "time": "2018-04-09",
            "original_text": "Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III",
            "features": {
                "keywords": [
                    "NVS",
                    "AveXis",
                    "PFE",
                    "ABBV",
                    "Phase III"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "Bristol-Myers Collaborates With Harvard Fibrosis Network",
            "features": {
                "keywords": [
                    "Bristol-Myers",
                    "Harvard",
                    "Fibrosis",
                    "Collaboration"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-11",
            "original_text": "Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why",
            "features": {
                "keywords": [
                    "Rigel",
                    "Pharmaceuticals",
                    "Stock Gains",
                    "RIGL"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 7,
                "Impact": 8,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-12",
            "original_text": "Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus",
            "features": {
                "keywords": [
                    "Gene Therapy",
                    "Novartis",
                    "Deal",
                    "Stocks in Focus"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-13",
            "original_text": "Glaxo to Sell Rare Disease Gene Therapies to Private Biotech",
            "features": {
                "keywords": [
                    "Glaxo",
                    "Rare Disease",
                    "Gene Therapies",
                    "Private Biotech"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-14",
            "original_text": "The Swiss Stock Market Finished Nearly Unchanged In Choppy Trade",
            "features": {
                "keywords": [
                    "Swiss Stock Market",
                    "Unchanged",
                    "Choppy Trade"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "market"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-04-15",
            "original_text": "These 3 Biotech Stocks Are Up More Than 500% Over the Last 3 Years",
            "features": {
                "keywords": [
                    "Biotech Stocks",
                    "Up More Than 500%"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 2,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-04-16",
            "original_text": "Same as the old boss â€” Novan makes interim CEO permanent",
            "features": {
                "keywords": [
                    "Novan",
                    "interim CEO",
                    "permanent"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "management"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        }
    ]
]